KLOTHO NEUROSCIENCES INC (KLTO) Stock Price & Overview
NASDAQ:KLTO • US49876K1034
Current stock price
The current stock price of KLTO is 0.5242 USD. Today KLTO is up by 0.81%. In the past month the price increased by 124.98%. In the past year, price increased by 84.97%.
KLTO Key Statistics
- Market Cap
- 38.55M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.33
- Dividend Yield
- N/A
KLTO Stock Performance
KLTO Stock Chart
KLTO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KLTO. When comparing the yearly performance of all stocks, KLTO is one of the better performing stocks in the market, outperforming 94.61% of all stocks.
KLTO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KLTO. No worries on liquidiy or solvency for KLTO as it has an excellent financial health rating, but there are worries on the profitability.
KLTO Earnings
KLTO Forecast & Estimates
KLTO Groups
Sector & Classification
KLTO Financial Highlights
Over the last trailing twelve months KLTO reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -38.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.08% | ||
| ROE | -113.73% | ||
| Debt/Equity | 0 |
KLTO Ownership
KLTO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.09 | 368.645B | ||
| AMGN | AMGEN INC | 15.3 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.67 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.37 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.91 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.9 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 10.92 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.86 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.32 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KLTO
Company Profile
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
Company Info
IPO: 2022-04-29
KLOTHO NEUROSCIENCES INC
13576 Walnut Street, Suite A
Omaha NEBRASKA US
Employees: 3
Phone: 18339316330
KLOTHO NEUROSCIENCES INC / KLTO FAQ
What does KLOTHO NEUROSCIENCES INC do?
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
What is the current price of KLTO stock?
The current stock price of KLTO is 0.5242 USD. The price increased by 0.81% in the last trading session.
Does KLOTHO NEUROSCIENCES INC pay dividends?
KLTO does not pay a dividend.
How is the ChartMill rating for KLOTHO NEUROSCIENCES INC?
KLTO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists KLTO stock?
KLTO stock is listed on the Nasdaq exchange.
Would investing in KLOTHO NEUROSCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KLTO.
Can you provide the market cap for KLOTHO NEUROSCIENCES INC?
KLOTHO NEUROSCIENCES INC (KLTO) has a market capitalization of 38.55M USD. This makes KLTO a Nano Cap stock.